Keros Therapeutics to receive $20 million Takeda milestone payment for elritercept Phase 3 dosingPUBT·1 day ago, 03:09 PMKROS-1.47%TAK-0.93%
Keros Therapeutics names Annita Tanini interim CFO as Keith Regnante resignsPUBT·Jul 22 at 03:02 PMKROS-1.47%
Keros Therapeutics Director Jean Jacques Bienaime buys USD 10,610 in common sharesPUBT·Jul 17 at 03:10 PMKROS-1.47%
Keros Therapeutics director Anne Prener files initial beneficial ownership statementPUBT·Jul 6 at 03:27 PMKROS-1.47%
Keros Therapeutics director Jean Jacques Bienaime buys $10,190 of common sharesPUBT·Jun 17 at 03:56 PMKROS-1.47%
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 99% UpsideTradingView·Jun 13 at 12:20 AMKROS-1.47%
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $21.83, Implies 107% UpsideTradingView·Jun 3 at 12:20 PMKROS-1.47%
Keros Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.benzinga_article·May 14 at 11:36 AMKROS-1.47%BBH-1.18%
Keros Therapeutics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 367 KEarnings Watch·May 14 at 07:03 AMKROS-1.47%
